Appropriate and Effective Use of Novel Oral Corticosteroid-Sparing Therapies to Optimize the Management of Severe Asthma

Released On
September 17, 2019

Expires On
September 17, 2020

Media Type

Completion Time
60 minutes

Allergy & Immunology, Pulmonology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Integrity Continuing Education, Inc.

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Program Overview

The availability of newer therapies has provided an opportunity to improve the management of patients with severe asthma. This program aims to ensure clinicians are able to differentiate severe asthma from difficult-to-treat asthma so patients who need these novel therapies are provided with them. The program will review the important role of phenotypes, endotypes, and biomarkers in severe asthma management and the utility of common biomarkers as predictive markers. Following this program clinicians will be able to utilize information from biomarker testing and clinical exam to select therapies that are appropriately individualized to specific patients, while also minimizing reliance on oral corticosteroids (OCS). Finally, adequate and personalized monitoring for response to therapy, adherence, patient satisfaction, and opportunities for optimizing therapy is critical. Therefore, this program will review strategies to identify and address these care considerations as well as what is known related to patient preferences for severe asthma therapy.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize available clinical guidelines to accurately diagnose patients with severe asthma vs difficult-to-treat asthma
  • Utilize strategies to minimize the use of OCS in patients with severe asthma in order to reduce OCS-related adverse effects and improve quality of life
  • Differentiate between asthma phenotypes and endotypes and utilize biomarkers to guide asthma diagnosis and predict response to therapy
  • Utilize available clinical trial data and readily available biomarkers to select the most appropriate therapy for individual patients
  • Describe strategies to effectively monitor patients with severe asthma in order to assess response to therapy, adherence to treatment, and opportunities to optimize therapy on an ongoing basis


Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Michael E. Wechsler, MD, MMSc

  • Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Equillium, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, RestorBio, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva
  • Contracted Research: AstraZeneca Pharmaceuticals LP, Sanofi Genzyme and Regeneron Pharmaceuticals

The Integrity Continuing Education, Inc. planners have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 17, 2019 through September 17, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or